All In Biotech

Drug Trial Radar · NCT03493685

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS

Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 371 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

371

Actual

Start

Apr 17, 2018

Primary completion

Mar 20, 2023

Study completion Mar 19, 2026

Sponsor

Lead sponsor
Travere Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 10, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 8 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS).

Conditions

  • Focal Segmental Glomerulosclerosis

Interventions

  • sparsentanDrug

    Double-blind period: target dose of 800 mg daily; Open-label extension: target dose based on dosage from week 114 daily

  • IrbesartanDrug

    target dose of 300 mg daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Slope of Estimated Glomerular Filtration Rate (eGFR)Time frame: From Day 1 to Week 108
  2. Percentage of Participants Achieving FSGS Partial Remission Endpoint (FPRE)Time frame: Week 36

Locations

226 sites in 22 countries. Site status is shown where the registry gives one.

  • Travere Investigational Site

    Mesa, Arizona

  • Travere Investigational Site

    Phoenix, Arizona

  • Travere Investigational Site

    Los Angeles, California

  • Travere Investigational Site

    Northridge, California

  • Travere Investigational Site

    Palo Alto, California

  • Travere Investigational Site

    San Diego, California

  • Travere Investigational Site

    San Dimas, California

  • Travere Investigational Site

    San Francisco, California

  • Travere Investigational Site

    Torrance, California

  • Travere Investigational Site

    Victorville, California

  • Travere Investigational Site

    Denver, Colorado

  • Travere Investigational Site

    Denver, Colorado

  • Travere Investigational Site

    Middlebury, Connecticut

  • Travere Investigational Site

    Wilmington, Delaware

  • Travere Investigational Site

    Washington D.C., District of Columbia

  • Travere Investigational Site

    Coral Springs, Florida

  • Travere Investigational Site

    Fort Lauderdale, Florida

  • Travere Investigational Site

    Gainesville, Florida

  • Travere Investigational Site

    Miami, Florida

  • Travere Investigational Site

    Miami, Florida

  • Travere Investigational Site

    Miami, Florida

  • Travere Investigational Site

    Ocala, Florida

  • Travere Investigational Site

    Orlando, Florida

  • Travere Investigational Site

    Port Charlotte, Florida

  • Travere Investigational Site

    Temple Terrace, Florida

  • Travere Investigational Site

    Winter Park, Florida

  • Travere Investigational Site

    Lawrenceville, Georgia

  • Travere Investigational Site

    Nampa, Idaho

  • Travere Investigational Site

    Chicago, Illinois

  • Travere Investigational Site

    Hinsdale, Illinois

  • Travere Investigational Site

    Kansas City, Kansas

  • Travere Investigational Site

    Wichita, Kansas

  • Travere Investigational Site

    Louisville, Kentucky

  • Travere Investigational Site

    Monroe, Louisiana

  • Travere Investigational Site

    New Orleans, Louisiana

  • Travere Investigational Site

    Shreveport, Louisiana

  • Travere Investigational Site

    Boston, Massachusetts

  • Travere Investigational Site

    Springfield, Massachusetts

  • Travere Investigational Site

    Ann Arbor, Michigan

  • Travere Investigational Site

    Detroit, Michigan

Showing 40 of 226 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.